Participants who took 70mg Zorevunersen had on average 50% fewer seizures after one dose and about 80% fewer after three doses. Photo Credit: Justin Kase zsixz/Alamy
Health United KingdomBreakthrough Treatment Offers New Hope for Severe Childhood Epilepsy
The United Kingdom reported promising 2026 trial results for a new drug that significantly reduces seizures in children with Dravet syndrome, improving quality of life for patients and families.
“This new treatment could help children with Dravet syndrome lead much healthier and happier lives,” said Helen Cross, professor of childhood epilepsy at UCL Institute of Child Health.
In early trials, led by UCL and Great Ormond Street Hospital (GOSH), involving 81 children aged two to 18, monthly seizures fell from an average of 17 to around 50% fewer after one dose of Zorevunersen and up to 80% fewer after three doses. The treatment was also found to be safe and well-tolerated, with additional improvements in motor skills, communication, and daily functioning. As one of more than 800 genetic epilepsies lacking targeted therapies, Dravet syndrome has long been difficult to treat, but these results mark a significant step toward addressing underlying causes rather than only managing symptoms, with larger phase 3 trials planned to confirm long-term benefits.
